Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lurbinectedin

FDA-approved product (powder, intravenous), marketed as Zepzelca.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Lurbinectedin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm
  • Small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antineoplastic agents
FDA pharmacologic class
Alkylating Drug FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae47.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lurbinectedin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lurbinectedin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer

    NCT07796100 · start 2026-12-31

    Registered record
    Registry ID
    NCT07796100
    Conditions
    Extensive-Stage Small Cell Lung Cancer
    Interventions
    ZL-1310 in combination with Atezolizumab or Durvalumab; Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin; Carboplatin/Etoposide or Cistplatin/Etoposide in Combination with Durvalumab induction followed by Durvalumab maintenance
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-12-31
    Completion
    2031-06-30
    Enrolment
    530

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExtensive-Stage Small Cell Lung Cancer
    InterventionZL-1310 in combination with Atezolizumab or Durvalumab; Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin; Carboplatin/Etoposide or Cistplatin/Etoposide in Combination with Durvalumab induction followed by Durvalumab maintenance
    PhasePhase 3
    Registry statusNot yet recruiting

  • A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

    NCT07459634 · start 2026-11-30

    Registered record
    Registry ID
    NCT07459634
    Conditions
    Extensive-stage Small-cell Lung Cancer
    Interventions
    Lurbinectedin; Durvalumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-11-30
    Completion
    2028-04-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExtensive-stage Small-cell Lung Cancer
    InterventionLurbinectedin; Durvalumab
    PhasePhase 2
    Registry statusRecruiting

  • Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer

    NCT07640932 · start 2026-11

    Registered record
    Registry ID
    NCT07640932
    Conditions
    Carcinoma, Small Cell Lung
    Interventions
    Lurbinectedin; Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-11
    Completion
    2029-02
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Small Cell Lung
    InterventionLurbinectedin; Paclitaxel
    PhasePhase 2
    Registry statusNot yet recruiting

  • Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases

    NCT07258147 · start 2026-10-31

    Registered record
    Registry ID
    NCT07258147
    Conditions
    Lung Cancer (SCLC)
    Interventions
    Immunotherapy; Chemotherapy (Etoposide, Nab-paclitaxel, Irinotecan, or Lurbinectedin); low-dose radiation; Stereotactic Body Radiation Therapy (SBRT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-31
    Completion
    2028-12-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer (SCLC)
    InterventionImmunotherapy; Chemotherapy (Etoposide, Nab-paclitaxel, Irinotecan, or Lurbinectedin); low-dose radiation; Stereotactic Body Radiation Therapy (SBRT)
    PhasePhase 2
    Registry statusNot yet recruiting

  • Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer

    NCT07153055 · start 2026-08

    Registered record
    Registry ID
    NCT07153055
    Conditions
    Small Cell Lung Cancer ( SCLC ); Transformed Small Cell Lung Cancer
    Interventions
    Lurbinectedin; Osimertinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2026-08
    Completion
    2029-10
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall Cell Lung Cancer ( SCLC ); Transformed Small Cell Lung Cancer
    InterventionLurbinectedin; Osimertinib
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

    NCT07365241 · start 2026-07-02

    Registered record
    Registry ID
    NCT07365241
    Conditions
    Small Cell Lung Cancer
    Interventions
    ABBV-706; Topotecan; Topotecan; Lurbinectedin; Amrubicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-07-02
    Completion
    2030-09
    Enrolment
    531

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall Cell Lung Cancer
    InterventionABBV-706; Topotecan; Topotecan; Lurbinectedin +1 more
    PhasePhase 3
    Registry statusRecruiting

  • Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC

    NCT06681220 · start 2026-02-23

    Registered record
    Registry ID
    NCT06681220
    Conditions
    Relapsed Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer
    Interventions
    Stenoparib/Temozolomide; Lurbinectedin; Stenoparib/Temozolomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2026-02-23
    Completion
    2030-12-31
    Enrolment
    166

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer
    InterventionStenoparib/Temozolomide; Lurbinectedin; Stenoparib/Temozolomide
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • An Exploratory Study of Lurbinectedin With Radiotherapy in SCLC With Single-lesion Progression After First Course Treatment

    NCT06501976 · start 2025-12-31

    Registered record
    Registry ID
    NCT06501976
    Conditions
    Small Cell Lung Carcinoma
    Interventions
    Lurbinectedin; Radiation Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2025-12-31
    Completion
    2027-06
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall Cell Lung Carcinoma
    InterventionLurbinectedin; Radiation Therapy
    PhasePhase 2
    Registry statusActive not recruiting

  • An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing

    NCT07141771 · start 2025-12-31

    Registered record
    Registry ID
    NCT07141771
    Conditions
    SCLC, Extensive Stage
    Interventions
    Serplulimab; Fluzoparib; Topotecan/Irinotecan/Paclitaxel/Temozolomide; Etoposide/Carboplatin/Cisplatin; Lurbinectedin; Temozolomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-12-31
    Completion
    2030-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSCLC, Extensive Stage
    InterventionSerplulimab; Fluzoparib; Topotecan/Irinotecan/Paclitaxel/Temozolomide; Etoposide/Carboplatin/Cisplatin +2 more
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

    NCT07155174 · start 2025-11-25

    Registered record
    Registry ID
    NCT07155174
    Conditions
    Small Cell Lung Cancer
    Interventions
    ABBV-706; Atezolizumab; Etoposide; Carboplatin; Carboplatin; Lurbinectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-11-25
    Completion
    2031-09
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall Cell Lung Cancer
    InterventionABBV-706; Atezolizumab; Etoposide; Carboplatin +2 more
    PhasePhase 2
    Registry statusRecruiting

  • Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS

    NCT07328425 · start 2025-11-21

    Registered record
    Registry ID
    NCT07328425
    Conditions
    Desmoplastic Small Round Cell Tumor
    Interventions
    Lurbinectedin; Irinotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-11-21
    Completion
    2030-10-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDesmoplastic Small Round Cell Tumor
    InterventionLurbinectedin; Irinotecan
    PhasePhase 2
    Registry statusRecruiting

  • Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

    NCT06801834 · start 2025-04-04

    Registered record
    Registry ID
    NCT06801834
    Conditions
    Extensive Stage Small Cell Lung Cancer (ES-SCLC)
    Interventions
    Sacituzumab Govitecan (SG); Topotecan; Amrubicin (Japan only); Lurbinectedin (regions/countries where approved and available)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-04-04
    Completion
    2029-10
    Enrolment
    695

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExtensive Stage Small Cell Lung Cancer (ES-SCLC)
    InterventionSacituzumab Govitecan (SG); Topotecan; Amrubicin (Japan only); Lurbinectedin (regions/countries where approved and available)
    PhasePhase 3
    Registry statusRecruiting

  • Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC

    NCT06497530 · start 2024-12-01

    Registered record
    Registry ID
    NCT06497530
    Conditions
    Extensive-Stage Small Cell Lung Cancer
    Interventions
    Serplulimab; Lurbinectedin; Carboplatin; Etoposide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-12-01
    Completion
    2026-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExtensive-Stage Small Cell Lung Cancer
    InterventionSerplulimab; Lurbinectedin; Carboplatin; Etoposide
    PhasePhase 2
    Registry statusRecruiting

  • Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas

    NCT06217536 · start 2024-10-31

    Registered record
    Registry ID
    NCT06217536
    Conditions
    Locally Advanced Soft Tissue Sarcoma
    Interventions
    Lurbinectedin; Radiotherapy; Non-investigational surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2024-10-31
    Completion
    2027-10-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced Soft Tissue Sarcoma
    InterventionLurbinectedin; Radiotherapy; Non-investigational surgery
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

    NCT06228066 · start 2024-06-13

    Registered record
    Registry ID
    NCT06228066
    Conditions
    Small Cell Carcinoma of the Bladder; High Grade Neuroendocrine Tumors of the Urinary Tract
    Interventions
    Lurbinectedin; Avelumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-06-13
    Completion
    2028-09-01
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall Cell Carcinoma of the Bladder; High Grade Neuroendocrine Tumors of the Urinary Tract
    InterventionLurbinectedin; Avelumab
    PhasePhase 2
    Registry statusRecruiting